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Abstract
Background: HIV has devastated numerous countries in sub-Saharan Africa and is a dominant health force in many other
parts of the world. Its undeniable importance is reflected in the establishment of Millennium Development Goal No. 6.
Unprecedented amounts of funding have been committed and disbursed over the past two decades. Many have argued
that this enormous influx of funding has been detrimental to building stronger health systems in recipient countries. This
paper examines the funding share for HIV measured against the total funding for health.
Methodology/Principal Findings: A descriptive analysis of HIV and health expenditures in 2007 from 65 countries was
conducted. Comparable data from individual countries was used by applying a consistent definition for HIV expenditures
and total health expenditures from NHAs to align them with National AIDS Assessment Reports. In 2007, the total public and
international expenditure in LMICs for HIV was 1.6 percent of the total spending on health, while the share in SSA was 19.4
percent. HIV prevalence was six-fold higher in SSA than the next highest region and it is the only region whose share of HIV
spending exceeded the burden of HIV DALYs.
Conclusions/Significance: The share of HIV spending across the 65 countries was quite moderate considering that the
estimated share of deaths attributable to HIV stood at 3.8 percent and DALYs at 4.4 percent. Several high spending
countries are using a large share of their total health spending for HIV health, but these countries are the exception rather
than representative of the average SSA country. There is wide variation between regions, but the burden of disease also
varies significantly. The percentage of HIV spending is a useful indicator for better understanding health care resources and
their allocation patterns.
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Introduction
HIV has had a devastating impact on many countries,
particularly those in sub-Saharan Africa (SSA). For example, the
life expectancy at birth in Botswana fell from 65 years in 1990 to
less than 40 years by 2005 [1]. This is largely attributed to the rise
and spread of HIV. Such trends have been similarly observed
across numerous other African countries. The world community
has responded positively to the HIV threat through investment of
funds and recognition of HIV as a global humanitarian crisis. In
2000, global leaders created the Millennium Development Goals
(MDG), with goal number six targeting HIV/AIDS, malaria and
tuberculosis [2]. In 2005, The Human Development Report
concluded that ‘‘the HIV/AIDS pandemic has inflicted the single
greatest reversal in human development’’ [3]. Containment of
HIV is understood to be a global public good which improves the
well-being of all citizens. Developed countries have raised
extraordinary funds for controlling this disease, with total funding
reaching US$ 15.6 billion in 2008 [4]. These initiatives are
responsible for mobilizing the largest amount of funding given to a
single disease in history.
One of the most discussed topics accompanying this extraor-
dinary amount of HIV funding is the debate between a silo
approach to health financing and a health systems strengthening
approach. Many have pointed to the fact that vertical programs,
those focused on a specific disease, may be diverting funds away
from horizontal programs [5], those interventions that strengthen
the entire health system [6]. Advocates of vertical programs point
to their service specialization, better accountability and rapid
results within weak health systems [7,8]. Others argue that disease-
focused approaches have been extremely successful in both their
primary goals as well as in their provision of marginal positive
externalities, as demonstrated by programs such as polio
eradication [9]. Alternatively, a third argument suggests integrat-
ing vertical programs within the existing health system in order to
maximize the positive synergies of both the health system and
specific programs [10,11,12].
As a result of such arguments, there are presently several major
donors, including the President’s Emergency Plan for AIDS Relief
(PEPFAR) [13] and The Global Fund to Fight AIDS, Tuberculosis
and Malaria (Global Fund), who are increasing their support of
health systems strengthening beyond their disease-specific man-
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country ownership of funding flows; PEPFAR’s stated goals
include to ‘‘integrate and coordinate HIV/AIDS programs with
broader global health and development programs to maximize
impact on health systems’’ [13]. Marchal et al. claim that while
health systems strengthening may be a stated goal of some major
organizations, their implementation falls short of desired outcomes
[14]. One potential solution, similar to PEPFAR’s recent goals,
involves providing recipient countries with more ownership in the
decision-making process [15]. These arguments are highly
controversial when it comes to HIV funding, which has escalated
in low- and middle-income countries (LMICs) from US$ 292
million [16] in 1996 to over US$ 15.6 billion in 2008 [4,17].
However, after years of ongoing debate regarding the potential
benefits or harms of vertical programs, there remains a paucity of
evidence upon which to develop informed policy decisions. This
may be partially explained by the difficult nature of conducting
rigorous research. There have been some attempts to explicate this
relationship between disease-specific funding and health system
performance. A few studies have looked at funding flows from the
Development Assistance Committee (DAC) and pointed to HIV’s
increasing percentage [6,18]. However, this fails to account for the
total amount of funding that is spent on health in these countries.
Understanding the share of HIV and total health resources is
critical to delineating the aid architecture in LMICs, where the
HIV burden often exceeds the available resources. Previous
reports argue that countries and donors often allocate more
resources to HIV than other health concerns [19]. Others assert
that HIV funding in various African countries may in actuality
exceed their entire budget for health, thus subverting national
priorities [20]. With both donor aid and government resources
affected by the global recession [21], it is imperative to achieve an
evidence-based understanding of resource allocation in order to
maximize health delivery.
This paper seeks to examine funding shares for HIV, especially
in SSA, using updated data from the World Health Organization
and the Joint United Nations Programme on AIDS (UNAIDS).
This allows for investigation of the share of funds allotted uniquely
to HIV and other specific diseases at both a global level as well as
within specific regions.
The authors’ objective is to use the most recent data on
domestic spending for total health and HIV, in order to analyze
expenditures reported from LMICS and to examine if HIV is
receiving a disproportionate share of resources. The paper
describes levels and patterns of domestic HIV spending from
public and international sources, while taking epidemic types and
country income levels into account.
Methods
A descriptive analysis of HIV and health expenditures in 2006–
7 from 65 countries was conducted. All expenditures, by
programmatic activity and HIV services, were cross-tabulated by
source of financing and stratified by income level. Spending
information from public and international sources was analyzed
based on the National AIDS Spending Assessment (NASA)
methods and classifications [22]. In order to examine HIV
funding flows, the authors used two data sets: 1) the 2006 and 2007
National AIDS Spending Assessment and 2) the 2007 data for
National Health Accounts (NHA) [23].
NASA is a tool developed by UNAIDS, based on the national
health accounts framework. which measures all resources
included in a country’s national HIV response [22,23]. The
National Health Accounts framework as well as NASA apply
standard accounting methods to reconstruct all transactions
in a given country, ‘following the money’ from the funding
sources to agents and providers and eventually to beneficiary
populations.
The NASA financial flows related to health and HIV activities
are organized into six areas : 1) financing sources (funding entities
that disburse money to agents); 2)agents (entities that receive and
pool financial resources, pay for service provision and make
programmatic decisions); 3) providers (entities that produce and
deliver HIV services); 4) production factors (resources used to
produce goods and services); 5) HIV spending categories (goods,
services and activities delivered as part of the HIV response); and
6) beneficiary populations (groups targeted by specific programs
and activities) [22]. Standardization of all NASA spending
categories across countries has been improved through the
publication of manuals in English, French, Portuguese, Spanish,
Russian and Arabic [22].
The NASA tool, developed by UNAIDS, represents the most
ambitious attempt to collect spending information at the national
level and to monitor expenditures at the global level [22]. NASA
was developed to produce accurate and detailed in-country
estimates of the actual expenditures of HIV programs and has
been used to report progress on the 2001 Declaration of
Commitment from the United Nations General Assembly Special
Session on HIV/AIDS (UNGASS). As of 2008, a total of 109
countries had reported domestic spending from international and
domestic sources [24].
National Health Accounts measure the various aspects of a
nation’s health expenditure. It implements a rigorous classification
of the types and purposes of all expenditures and of all the actors in
the health system, and provides a complete accounting of all
spending for health, regardless of the origin, destination, or object
of the expenditure [23]. The most reliable NHA data are broken
down by the private and government agents who spent health
funds. Out-of-pocket (OOP) expenditures and spending on private
insurance were excluded in order to match the NASA data, which
does not contain private expenditures. The remaining balance was
the total amount of spending on health from public and
international sources. Due to the difficulty in collecting private
expenditure data on health for HIV, only the total public and
international expenditures from the NHA and NASA data were
used. Additionally, in order to produce meaningful comparisons
among countries, all expenditures were put into current 2007
dollars.
Thus, this study used comparable data from individual countries
by applying a consistent definition for HIV expenditures and total
health expenditures from NHA. The 2007 NASA database
provided 71 countries, 15 of which were excluded either because
they had low levels of spending on HIV, had a low percentage of
representative countries in the region or were high income
countries (Sao Tome, Seychelles, UK overseas territories, Palau, St
Kitts Nevis, Cuba, Trinidad and Tobago, Egypt, Kuwait, Syria,
Fiji, Czech Republic, Hungary, Spain, and the United Kingdom).
By taking the 2006 NASA data and applying a regional growth
rate based on regression analysis of previous data, 32 additional
countries were added, of which 11 were excluded based on the
aforementioned criteria (Bahamas, Haiti, Saint Lucia, Cape
Verde, Equatorial Guinea, North Sudan, South Sudan, Mongolia,
Australia, Algeria, and Switzerland). Within the NASA database,
expenditures that were used for health and those that were used
for non-health purposes were distinguished. Western and Central
Europe (WCE) included a low number of countries with available
data, but it was included in the data set in order to capture the few
LMICs in the region.
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both health and HIV by region were used to calculate the percent
of total regional health resources being used for HIV. In SSA, the
total HIV spending was biased downward due to the lack of
spending data from South Africa, which alone added approxi-
mately US$ 1 billion in HIV health spending in 2010 [25]. In
order to avoid leaving out this important country a sensitivity
analysis was performed, using a conservative estimate of US$ 700
million spent for HIV health in 2007.
Categorization was determined by applying a three-tiered
decision-making rubric specific to health spending: 1) ‘‘activities
whose primary purpose is to restore, improve and maintain health
for the nation and for individuals,’’ consistent with WHO’s
definition of health [23]; 2) activities that took place within the
health system; and 3) actions that were administered by personnel
who received compensation from the health sector. The first
criterion served as the most important, and the additional criteria
were used to clarify the classification if further questions remained.
All items not broken down by type or not classified were excluded
from this analysis.
Using the above-described rating system, two researchers
categorized 136 lines of NASA expenditures independently with
96.3 percent agreement (kappa .875 p,.0001). The remaining five
lines of discordance were sent to a third independent party for
review. If further questions arose, all three researchers discussed
and determined the appropriate classification. Health and HIV
spending categories were then matched by using a previously
published cross-walk tool [26]. This ratio of health to non-health
spending was then applied to total HIV expenditures in LMICs as
well as to the individual country spending on HIV to obtain
country-specific values for the total HIV spending on health.
For regional analyses, the country-specific proportion of HIV
spending for health and total health expenditure were adjusted for
population size [27]. The total regional HIV health spending and
health expenditures were divided by the size of the population to
obtain per capita rates for each region. For the 65 country
analysis, all HIV expenditures were totaled and taken out of the
aggregate spending on health of those 65 countries to report HIV
spending as a share of total health spending.
Countries were classified by region and income level. Econo-
mies were ordered according to their Gross National Income
(GNI) per capita for the data collection year used, according to the
World Bank Atlas Methods [28] and grouped into four categories:
low-income (US$ 935 or less); lower middle-income (US$ 936–
$3,705); upper middle-income (US$ 3,706–$11,455); and high
income (US$ 11,456 or more). Out of the 65 countries, there were
28 low-income countries, 20 lower middle-income countries and
17 upper middle-income countries.
In order to compare various indicators of HIV’s global impact,
2004 projections from the Global Burden of Disease Report were
used, including disability-adjusted life years (DALYs) and the
percent of deaths attributable to HIV, to calculate 2008
predictions [29]. Additionally, estimates of HIV prevalence
published in the 2008 UNAIDS Global Report were obtained
[24]. These 2008 indicators were used in order to compare a
burden of disease measure against the 2007 spending data.
Western and Central Europe were left out of this burden of disease
analysis because the large number of high-income countries in that
region would likely bias these measures in a downward direction.
Additionally, the correlation was examined and a regression was
performed on HIV spending on health and prevalence in SSA.
Prevalence was available for all but two of the study countries in
SSA (Kenya, Democratic Republic of Congo) [24].
Results
Due to the large variation in global HIV spending, five regions
were examined separately—sub-Saharan Africa, South East Asia
(SEA), Eastern Europe and Central Asia (EECA), Western and
Central Europe, and Central and South America (CSA). The
study was able to incorporate 67, 45, 75, 16 and 76 percent of the
countries from these regions in our data set, respectively. Sub-
Saharan Africa countries spent 19.4 percent of their total health
expenditures on HIV-related activities, compared to CSA
spending of less than 1.1 percent. There were wide variations in
spending patterns across regions.
Looking at all 65 LMICs included in the analysis, overall HIV
spending was overwhelmingly directed to health activities, which
comprise 95.1 percent of spending. This represented more than
US$3.87 billion spent on HIV health in the 65 LMICs [22]. The
remaining 4.9 percent went to activities such as human rights and
support for orphans and vulnerable children. After applying the
ratio of spending for HIV health, the total public and international
expenditure in LMICs for HIV was 1.6 percent of the total
spending on health in 2007. Figure 1 shows HIV spending as a
share of total health spending in the 65 included countries
compared against the share in SSA. The spending ratio for
countries from SSA was significantly higher at 19.4 percent, thus
predicating the need for regional analyses to further understand
this discrepancy.
Table 1 shows a detailed breakdown of the spending across all
the included countries. The 28 SSA countries in our study spent
US$ 2 billion on HIV health, but their total health expenditure
was only US$ 10.56 billion (Table 1). South and South East Asia
spent US$ 517 million for HIV health, but their total spending on
health of US$ 83.35 billion was more than 8 times the spending in
SSA. Spending US$ 1.04 billion, the 13 CSA countries were the
other major regional spender of HIV funds, but they spent over
US$ 90.37 billion on total health. The 28 SSA countries spent a
population-weighted average of US$ 4.08 per capita on HIV
health, with the next highest region being CSA at US$ 2.63 per
capita. SEA, WCE and SEA spent much less on HIV health, with
per capita estimates of US$ 1.34, 0.97 and US$ 0.27 respectively.
However, the population-weighted average of total health
expenditure per capita was highest in WCE (US$ 413), followed
by CSA (US$ 229), EECE (US$ 114), SEA (US$ 43) and SSA
(US$ 21). Sub-Saharan Africa spent more per capita than any
other region on HIV and less per capita than any other region on
health.
Figure 1. HIV Spending as a Share of Total Health Spending.
doi:10.1371/journal.pone.0012997.g001
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Region Year HIV Hlth. Spending Tot. Hlth. Spending Population HIV/Cap. THE/Cap. Pct. HIV
Sub Saharan Africa (SSA)
Angola 2007 47,433,144 $ 1,208,137,245 17,432,462 $ 2.72 $ 69.30 3.9%
Benin 2007 16,625,950 $ 138,738,963 8,514,502 $ 1.95 $ 16.29 12.0%
Botswana 2007 225,640,838 $ 646,084,124 1,907,226 $ 118.31 $ 338.76 34.9%
Burkina Faso 2007 31,410,046 $ 254,145,067 14,192,090 $ 2.21 $ 17.91 12.4%
Burundi 2007 23,839,832 $ 84,601,892 10,274,028 $ 2.32 $ 8.23 28.2%
Cameroon 2007 34,028,774 $ 303,430,563 18,987,350 $ 1.79 $ 15.98 11.2%
Central African Republic 2007 10,036,489 $ 26,661,144 4,277,353 $ 2.35 $ 6.23 37.6%
Chad 2007 8,539,370 $ 194,451,605 10,645,391 $ 0.80 $ 18.27 4.4%
Congo 2007 8,331,154 $ 129,389,566 3,598,672 $ 2.32 $ 35.95 6.4%
Cote d’Ivoire 2007 65,083,758 $ 196,221,558 20,141,042 $ 3.23 $ 9.74 33.2%
Democratic Republic of
the Congo
2007 41,400,874 $ 338,130,627 63,321,852 $ 0.65 $ 5.34 12.2%
Gabon 2007 10,141,115 $ 341,681,079 1,430,887 $ 7.09 $ 238.79 3.0%
Gambia 2007 4,520,858 $ 25,880,928 1,594,061 $ 2.84 $ 16.24 17.5%
Ghana 2007 50,208,139 $ 727,597,567 23,159,938 $ 2.17 $ 31.42 6.9%
Guinea-Bissau 2007 2,743,907 $ 14,029,930 1,560,424 $ 1.76 $ 8.99 19.6%
Kenya 2007 387,792,495 $ 638,894,806 37,281,276 $ 10.40 $ 17.14 60.7%
Lesotho 2007 47,667,567 $ 74,042,553 2,020,214 $ 23.60 $ 36.65 64.4%
Mali 2007 37,784,390 $ 218,723,853 11,938,333 $ 3.16 $ 18.32 17.3%
Mauritius 2007 1,190,477 $ 167,117,827 1,290,096 $ 0.92 $ 129.54 0.7%
Mozambique 2007 95,536,946 $ 346,764,475 20,200,475 $ 4.73 $ 17.17 27.6%
Niger 2007 13,750,129 $ 123,241,597 13,863,271 $ 0.99 $ 8.89 11.2%
Nigeria 2007 293,159,644 $ 2,865,597,438 149,055,456 $ 1.97 $ 19.23 10.2%
Rwanda 2007 67,543,637 $ 250,393,827 9,020,701 $ 7.49 $ 27.76 27.0%
Sierra Leone 2007 8,552,918 $ 41,731,554 5,281,803 $ 1.62 $ 7.90 20.5%
Swaziland 2007 31,888,189 $ 135,017,628 1,169,010 $ 27.28 $ 115.50 23.6%
Togo 2007 9,548,938 $ 52,277,189 6,462,731 $ 1.48 $ 8.09 18.3%
Uganda 2007 265,894,160 $ 529,227,579 31,557,498 $ 8.43 $ 16.77 50.2%
Zambia 2007 210,053,166 $ 490,992,403 12,341,879 $ 17.02 $ 39.78 42.8%
Total 2,050,346,903 $ 10,563,204,588 502,520,021 $ 4.08 $ 21.02 19.4%
South East Asia (SEA)
Cambodia 2007 53,090,860 $ 204,427,023 14,973,597 $ 3.55 $ 13.65 26.0%
China 2007 100,279,089 $ 65,166,022,589 1,338,070,144 $ 0.07 $ 48.70 0.2%
Indonesia 2007 57,708,323 $ 6,359,737,447 246,797,488 $ 0.23 $ 25.77 0.9%
Lao P.D.R 2007 4,861,487 $ 62,128,802 6,130,845 $ 0.79 $ 10.13 7.8%
Myanmar 2007 30,896,670 $ 56,553,335 56,819,456 $ 0.54 $ 1.00 54.6%
Nepal 2007 13,809,296 $ 249,187,332 25,807,662 $ 0.54 $ 9.66 5.5%
Phillipines 2007 4,739,170 $ 2,161,837,171 90,326,120 $ 0.05 $ 23.93 0.2%
Thailand 2007 192,900,000 $ 6,906,190,585 63,024,352 $ 3.06 $ 109.58 2.8%
Vietnam 2007 59,409,994 $ 2,191,187,287 87,492,048 $ 0.68 $ 25.04 2.7%
Total $ 517,694,889 $ 83,357,271,570 1,929,441,712 $ 0.27 $ 43.20 0.6%
Eastern Europe Central Asia (EECA)
Armenia 2007 2,293,193 $ 210,565,980 3,062,720 $ 0.75 $ 68.75 1.1%
Azerbaijan 2007 2,220,238 $ 422,935,788 8,873,190 $ 0.25 $ 47.66 0.5%
Belarus 2007 17,191,815 $ 2,350,801,732 9,899,022 $ 1.74 $ 237.48 0.7%
Georgia 2007 6,738,971 $ 229,272,673 4,351,759 $ 1.55 $ 52.69 2.9%
Kazakstan 2007 17,340,373 $ 2,593,020,220 16,150,466 $ 1.07 $ 160.55 0.7%
Kyrgyzstan 2007 10,594,974 $ 143,186,758 5,443,675 $ 1.95 $ 26.30 7.4%
Republic of Moldova 2007 8,185,739 $ 235,531,558 3,961,192 $ 2.07 $ 59.46 3.5%
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Africa, was US$ 2.05 billion, accounting for 19.4 percent of global
HIV spending. The total expenditure on health in the 28 included
SSA countries was only US$ 10.5 billion, accounting for
approximately 2.6 percent of global health spending. There is a
high prioritization of HIV in overall health spending in SSA and
when looked at through the lens of morbidity and mortality
attributable to HIV in 2008 [27], the proportion of funding for
HIV in SSA is higher than the burden of disease (Figure 2).
However, in the other regions, this is not the case.
Figure 2 illustrates the share of expenditures devoted to HIV
spending and HIV DALYs by region. HIV prevalence in SSA is
six-fold higher than the global prevalence; DALYs due to HIV in
SSA are more than 5 times that of the EECA, which has the next
highest value, and SSA’s percent of deaths attributable to HIV is
almost 10 times greater than CSA, which is the region with the
next highest rate [27]. However, the share of spending for HIV
only exceeds the share of HIV DALYs in SSA.
Correlation of HIV spending on health with the HIV
prevalence of the SSA countries was 0.33 (p=.10). The naı ¨ve
model, including HIV spending and prevalence, showed that a
one percent increase in prevalence led to a US$ 3,738,545
(p=.10) increase in HIV spending; however, this model only
explained 10 percent of the variation. In order to account for
omitted variable bias, total health spending, foreign direct
investment (FDI), population size and GDP were included in the
regression model. Table 2 shows the different models and their
significance levels. With the inclusion of these additional variables
into the model, a one unit increase in HIV prevalence led to an
increase in HIV spending of US$ 3,964,055 (p,0.05) holding total
health spending, FDI, GDP and population size constant. The r-
Figure 2. Percent Share of HIV Spending and HIV DALYS by
Region.
doi:10.1371/journal.pone.0012997.g002
Region Year HIV Hlth. Spending Tot. Hlth. Spending Population HIV/Cap. THE/Cap. Pct. HIV
Tajikistan 2007 5,113,815 $ 59,433,551 6,808,692 $ 0.75 $ 8.73 8.6%
Ukraine 2007 72,539,355 $ 5,845,343,798 47,665,032 $ 1.52 $ 122.63 1.2%
Total $ 142,218,474 $ 12,090,092,057 106,215,748 $ 1.34 $ 113.83 1.2%
Western and Central Europe (WCE)
Bulgaria 2007 6,520,255 $ 1,819,152,063 7,811,891 $ 0.83 $ 232.87 0.4%
Croatia 2007 8,907,939 $ 3,893,841,620 4,400,000 $ 2.02 $ 884.96 0.2%
Latvia 2007 6,943,584 $ 1,036,168,133 2,187,549 $ 3.17 $ 473.67 0.7%
Montenegro 2007 1,468,956 $ 257,974,244 625,000 $ 2.35 $ 412.76 0.6%
Poland 2007 41,154,420 $ 20,512,787,004 38,625,876 $ 1.07 $ 531.06 0.2%
Turkey 2007 55,745,494 $ 24,023,076,923 71,158,647 $ 0.78 $ 337.60 0.2%
Total $ 120,740,648 $ 51,542,999,987 124,808,963 $ 0.97 $ 412.98 0.2%
Central and South America (CSA)
Argentina 2007 201,133,620 $ 13,981,548,387 39,627,972 $ 5.08 $ 352.82 1.4%
Bolivia 2007 3,130,254 $ 462,091,726 9,798,686 $ 0.32 $ 47.16 0.7%
Brazil 2007 554,330,346 $ 49,064,102,564 195,902,528 $ 2.83 $ 250.45 1.1%
Colombia 2007 68,096,518 $ 10,607,841,110 45,953,956 $ 1.48 $ 230.84 0.6%
Costa Rica 2007 13,844,314 $ 1,587,316,403 4,608,883 $ 3.00 $ 344.40 0.9%
Ecuador 2007 7,378,944 $ 1,364,000,000 13,900,130 $ 0.53 $ 98.13 0.5%
El Salvador 2007 37,661,693 $ 739,300,000 6,119,093 $ 6.15 $ 120.82 5.1%
Honduras 2007 17,621,759 $ 505,873,016 7,586,580 $ 2.32 $ 66.68 3.5%
Panama 2007 17,453,947 $ 855,200,000 3,464,820 $ 5.04 $ 246.82 2.0%
Paraguay 2007 2,221,986 $ 302,543,495 6,353,777 $ 0.35 $ 47.62 0.7%
Peru 2007 30,340,512 $ 2,744,141,755 29,386,596 $ 1.03 $ 93.38 1.1%
Uruguay 2007 6,687,997 $ 1,405,363,471 3,397,766 $ 1.97 $ 413.61 0.5%
Venezuala 2007 78,868,467 $ 6,753,636,207 28,267,160 $ 2.79 $ 238.92 1.2%
Total $ 1,038,770,358 $ 90,372,958,134 394,367,947 $ 2.63 $ 229.16 1.1%
doi:10.1371/journal.pone.0012997.t001
Table 1. Cont.
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almost three-quarters of the variation in health spending.
A sizeable divergence between the highest and lowest country-
specific values for spending within SSA was apparent. Several
countries, including Zambia, Uganda, Kenya, and Lesotho spent a
significant portion of their total health spending on HIV, ranging
from 42–64 percent (Table 1). More specifically, Kenya and
Lesotho were the highest spenders, allocating more than 60
percent of their health spending to HIV. Botswana spent almost
US$ 118 per capita on HIV health compared to the average of
US$ 9.34 in the rest of SSA. However, they also had an HIV
prevalence of 23.9 percent in 2007. While there are high spenders,
it seems that spending is often in proportion to the overall burden
of HIV, as was suggested by the regression of HIV spending and
prevalence. However, a few countries such as Burundi, Niger, and
Rwanda spent relatively high amounts compared to their low
burden of HIV. Burundi spent 28 percent of their health spending
while having a prevalence of only 2 percent. Most countries follow
rational spending patterns, while a few outliers’ spending may be
reliant on other unknown factors.
Discussion
The share of overall health spending allocated to HIV reached
1.6 percent in 2007. This is quite moderate considering that the
estimated share of deaths attributable to HIV stood at 3.8 percent
and DALYs at 4.4 percent [27]. However, the share of spending
for HIV varies significantly by region. In SSA, the 28 included
countries spent 19.4 percent of their total health spending on HIV,
while EECA spent 1.2 percent and CSA spent 1.1 percent. This
variation between regions is possibly due to differences in the HIV-
related burden of disease. Other explanations include factors such
as political will of the government or prioritization of HIV by
donors. The percentage of total spending on HIV only exceeds the
percent burden of HIV deaths and HIV DALYs in SSA. Globally,
there seems to be a shortage of spending on HIV, with higher
spending patterns in SSA. In fact, if the unit costs of treating HIV
are significantly higher than other diseases, this could indicate
dramatic under-spending on HIV globally. On the other hand, if
diseases like malaria generate even worse outcomes in terms of
total deaths or DALYs than HIV, then perhaps less money should
be spent at the margin on HIV and more transferred to malaria.
This should be the subject of future study.
Critics may point to high spending shares on HIV health as
evidence of the over-prioritization of HIV in SSA. However, the
claim that HIV is receiving a disproportionate share of global
health resources for HIV health may be invalidated when
interpreted in light of burden of disease indicators—HIV DALYs,
percentage of HIV deaths and HIV prevalence. Moreover, these
indicators may not have a one-to-one correlation with HIV
spending due to the fact that these indicators are better suited to
deal with the cost of HIV management related to morbidity and
mortality [30] and do not reflect population prevention needs.
Within the region, the countries with higher HIV prevalence spent
more than those countries that had a lower HIV prevalence. This
finding seems reasonable and it may also point to the need to
invest in preventive programs.
Several high spending countries are using a large share of their
total health spending for HIV health, but these countries are the
exception rather than representative of the average SSA country.
The NASA and NHA data provide a useful starting point in trying
to understand the effect of HIV funding, but these descriptive data
alone cannot definitively answer the causal question of whether
HIV funding is hurting the health system. Donors and researchers
have tried to assess the impact of HIV funding, but with few
successes. Direct evidence that mortality and morbidity have
dropped at the country level due to HIV funding is lacking.
There is considerable variation in overall spending among
regions. The region with the highest spending was SSA, which
spent over 19 percent of their total health spending on HIV health.
Inclusion of conservative estimates for South Africa decreases this
value to 13 percent. This is mostly due to the fact that South Africa
spent US$ 10.72 billion on health, more than the 28 included
countries combined. When looking at the included countries in
SSA it was found that prevalence and population size predicted
over 58 percent of the HIV health expenditures. This is clear
evidence of rational funding based on these countries’ overall
needs as they were related to the burden of disease due to HIV.
While there are outlier countries such as Burundi, Rwanda and
Niger, the overall spending patterns reflect an evidence-based
allocation of funding in these countries.
While the share of spending for HIV is high in SSA compared
to other regions, it is certainly not overwhelming the majority of
health budgets as is often claimed. However, a few countries,
including Zambia, Uganda, Kenya, and Lesotho are spending
more than 40 percent of their health budgets on HIV/AIDS. Such
a financing arrangement lacks sustainability due to disproportion-
ate spending on a single disease process. However, it is not clear if
these are accurate measures, artifacts of under-reported total
health spending, or miscommunication between HIV spending
and health spending reporting mechanisms. If this imbalance
reflects reality, other health services are likely suffering. One must
Table 2. HIV Prevalence as a Predictor of HIV Spending.
Variable model1 model2 model3 model4 model5
HIV Health Spending
Prevalence 3,738,545 3,964,055 4,004,986 4,433,100 3,885,668
Health Spending .102*** .0838* 0.0535 .246**
FDI 0.0111 0.00326 20.00452
Population 0.966 4.14*
GDP 2.00333**
Constant 39,216,214 109,965 276,905 21,615,432 222,075,285
R
2 0.108 0.586 0.598 0.607 0.739
Legend: * p,0.05; ** p,0.01; *** p,0.001.
doi:10.1371/journal.pone.0012997.t002
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of different health systems strengthening initiatives. If this is the
case, such an imbalance in funding is less concerning because HIV
funds would be simultaneously bolstering the overall health
system. On the whole, most countries are spending rational
amounts based on the impacts of HIV and the claims that SSA is
over-spending seem to be unsubstantiated except in a few select
countries.
Considerable opportunities remain for additional research on
this topic. Further analysis of country-specific allocation of funds
should be undertaken in order to understand the possible
mismatch between HIV health spending and overall health
spending. Examination of donors’ claims that a large proportion
of their funds support health systems strengthening activities would
be of particular interest. For example, PEPFAR claims that only
48 percent of their 2008 funding went to treatment, with the
remainder supporting prevention and care [31]. Similarly, the
Global Fund claims that it has helped 4.9 million orphans,
provided voluntary counseling and testing (VCT) to 46 million
people and trained 7.6 million people to provide care for HIV/
AIDS, TB and malaria [32]. And the World Bank’s Multi-Country
HIV/AIDS Programme (MAP) has stated that one of the four
areas of focus in SSA was ‘‘strengthening health systems,’’ which
includes training staff, building infrastructure and improving
supply chains for drugs and testing kits [33].
Health systems strengthening is clearly a stated priority of
donors and a significant portion of spending undoubtedly benefits
the surrounding health system in recipient countries. But it is
difficult to determine the extent to which VCT, blood screening,
prevention of mother-to-child transmission, infrastructure and
improved supply chains provide secondary benefits. The literature
is still lacking in evidence which quantifies the effects of donor
funding.
While this study undertook a novel means of quantifying and
categorizing health spending, it faced several limitations. First, the
lack of NASA data regarding private expenditures prohibited
assessment of individual-level spending on HIV health. The NHA
classification of agents is not specific enough to include public and
international funding due to some of the broad categories. In order
to address this limitation, NHA data that were clearly private
expenditures, OOP and private insurance, were eliminated from
analyses; the remaining expenditures were clearly public or
international. This distinction ensured comparability between
NASA and NHA data. However, private expenditures may be a
substitute for public expenditures which could bias the analysis;
but, these data are not available for HIV spending in the NASA
database.
The regression analysis and correlations showed a significant
effect between the levels of HIV spending and prevalence, but this
analysis may be limited due to the small sample size. Also, the data
used here are descriptive, which may help to explain how
resources are being used both across regions and globally;
however, they cannot be used to make claims of causality. In
order to better understand the potential positive or negative
synergies of HIV programs, randomized control trials or rigorous
quasi-experimental studies need to be conducted.
This paper is unable to solve the debate around vertical
programs or elucidate the impact of donor funding for HIV on the
overall health system. However, the total spending on HIV as a
share of health expenditures regionally is a good indicator to better
understand HIV spending patterns. It offers evidence which
suggests appropriate allocation of funds according to disease
burden in most SSA countries. A few countries demonstrated
spending profiles which fail to align with their country-specific
burden of disease and should be the subject of further study.
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